Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

iECURE Says Updated OTC-HOPE Low-Dose Data Showed 74% Reduction In Annualized Hyperammonemic Crises, 57% Reduction In Hyperammonemic Events; Completes Phase 1/2 Dosing Across All Three Cohorts | WAPE

Back All news

Newsbenzinga

iECURE Says Updated OTC-HOPE Low-Dose Data Showed 74% Reduction In Annualized Hyperammonemic Crises, 57% Reduction In Hyperammonemic Events; Completes Phase 1/2 Dosing Across All Three Cohorts

Aug 27, 2026, 08:07 ET · Published

View source

Article summary

Please check the source for details.

An excerpt from the original article.

Related companies

DTILDTILView stock

Analyzed by WAPE AI.

Positive B+

DTIL reports positive clinical data and completes Phase 1/2 dosing.

The reduction in hyperammonemic events is a significant clinical milestone for the company's therapeutic program.

Article summary

Related companies

Analyzed by WAPE AI.

DTIL reports positive clinical data and completes Phase 1/2 dosing.

Comments —